



## Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign

April 30, 2009

"Coping with Cancer from the Outside In" Program to Launch at the Annual Oncology Nursing Society Congress

THOUSAND OAKS, Calif., April 30 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and ONSEdge, a subsidiary of the Oncology Nursing Society (ONS), today announced that they will partner alongside celebrity make-up artist and cancer survivor Jan Ping to support a new educational campaign, Coping with Cancer From the Outside In. The initiative is aimed at educating oncology nurses about the skin-related side effects associated with epidermal growth factor receptor (EGFR) inhibitors that are used to treat metastatic colorectal, lung, pancreatic, and head and neck cancers.

To view the Multimedia News Release go to: <http://www.prnewswire.com/mnr/amgen/37919/>

(Photo: <http://www.newscom.com/cgi-bin/prnh/20090430/NY08415>)

EGFR inhibitor therapy aims to interrupt tumor growth by disrupting signals sent from the epidermal growth factor receptor, which is found on the surface of some cancer cells. Because EGFR is also present on other normal cells in the body, including skin cells, skin rash occurs in up to 90 percent of patients undergoing treatment with an EGFR inhibitor. This can be serious and potentially life threatening. Further, in its mild-to-moderate state, skin rash can cause patients physical discomfort and take an emotional toll, affecting body image. For most patients these side effects are mild, but moderate or severe toxicities that lead to dose modification or interruption develop in 8-17 percent of patients. Other appearance-related side effects include nail changes, skin cracking and hair disorders.

"Oncology nurses serve as a patient's advocate and help them manage the side effects of cancer therapy," said Beth A. Zupal, RN, oncology nurse practitioner at the Washington University School of Medicine in St. Louis, Missouri. "We are happy to be providing nurses with important educational tools."

The campaign will kick off at the Annual ONS Congress on April 30, 2009 in San Antonio, TX, where leading oncology experts and Jan Ping will host an informational seminar on coping with the appearance-related side effects that can accompany EGFR inhibitor treatments, along with other tips nurses can provide to both male and female patients for looking their best during treatment. Seminar attendees will be invited to a meet-and-greet reception with Jan Ping and guest speakers, and will be supplied with educational materials.

Jan Ping, an Emmy(R) Award-winning make-up artist known for her work on E! Entertainment's Chelsea Lately Show and the Tyra Banks Show, and her work with celebrities such as Cindy Crawford and Warren Beatty, was diagnosed with breast cancer at age 45 and knows from her own experience that a patient's body changes while undergoing cancer treatment. But despite her altered appearance, Ping maintained a positive outlook, and she will lend her beauty and skin care expertise to the campaign to help patients feel confident about their appearance during treatment. "I'm excited to be taking part in an important program that provides oncology nurses with everyday tips they can teach patients to boost confidence during a difficult time."

Following the campaign launch at the Annual ONS Congress, local training seminars will also be held in the second half of this year in New York City, Los Angeles, and Miami. To obtain more information, please call ONSEdge at 877-588-3343 or visit [www.onsedge.com](http://www.onsedge.com).

### About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics has changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit [www.amgen.com](http://www.amgen.com).

### Forward-Looking Statements

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Dec. 16, 2008 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or

manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

SOURCE Amgen